All Updates

All Updates

icon
Filter
Funding
Athos Therapeutics raises USD 35 million Series B to develop treatments for autoimmune diseases
AI Drug Discovery
Feb 16, 2024
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Feb 16, 2024

Athos Therapeutics raises USD 35 million Series B to develop treatments for autoimmune diseases

Funding

  • California-based AI drug discovery company Athos Therapeutics has secured USD 35 million in a Series B funding round. The investors were not disclosed.

  • The proceeds will support the development of treatments for autoimmune diseases and cancer, with USD 10 million specifically allocated to develop treatments for inflammatory bowel disease (IBD).

  • Founded in 2019, Athos Therapeutics develops novel small-molecule precision therapeutics targeting autoimmune diseases and cancers using AI-based medicinal chemistry and computational platforms. It also maintains a database of clinical and molecular datasets to identify novel drug targets. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.